Colon Cancer

Biothera Initiates Phase Ib/IIa Clinical Trial with Imprime PGG and Erbitux in Metastatic Colorectal Cancer Patients

Published in Immunotherapy Weekly, October 24th, 2007

Biothera announced that it has initiated enrollment of patients in a phase Ib/IIa clinical trial to evaluate the safety and efficacy of Imprime PGG(TM) and Erbitux(R) in patients with metastatic colorectal cancer.

Imprime PGG is a unique biological response modifier that enhances specific innate immune cell responses without inducing pro-inflammatory cytokines. Erbitux (cetuximab) is a monoclonal antibody from ImClone Systems that is approved for treatment of colorectal and head and neck cancer.

Numerous xenograft mouse models have demonstrated that combining Imprime PGG and Erbitux or other anti-tumor monoclonal antibodies, including Avastin(R)...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Immunotherapy Weekly

Source: Immunotherapy Weekly (2007-10-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry